Claims for Patent: 9,642,913

Summary for Patent: 9,642,913

Title:	Pharmaceutical composition including alkyl glycoside and an anti-seizure agent
Abstract:	A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
Inventor(s):	Maggio; Edward T. (San Diego, CA)
Assignee:	Aegis Therapeutics, LLC. (San Diego, CA)
Application Number:	14/152,686
Patent Claims:	1. An intranasal pharmaceutical composition comprising a suitable nontoxic, nonionic alkyl glycoside in combination with a compound that affects the central nervous system, wherein the compound is an anti-seizure agent, wherein the alkyl glycoside comprises dodecyl-.beta.-D maltoside at a concentration in the range of about 0.01% to 1.0%, and wherein the dodecyl-.beta.-D maltoside increases absorption and bioavailability of the compound in cerebrospinal fluid (CSF) of a subject. 2. The pharmaceutical composition of claim 1, in a format selected from the group consisting of a drop, a spray, an aerosol and a sustained-release format. 3. The pharmaceutical composition of claim 1, further comprising a mucosal delivery-enhancing agent selected from the group consisting of citric acid, sodium citrate, propylene glycol, glycerin, ascorbic acid, sodium metabisulfite, ethylenediaminetetraacetic acid (EDTA) disodium, benzalkonium chloride, sodium hydroxide, and combinations thereof. 4. An intranasal pharmaceutical composition comprising a suitable nontoxic, nonionic alkyl glycoside in combination with a compound that affects the central nervous system, wherein the compound is an anti-seizure agent, wherein the alkyl glycoside has a hydrophile-lipophile balance number in the range of about 10 to 20 and comprises dodecyl-.beta.-D maltoside, and wherein the dodecyl-.beta.-D maltoside increases absorption and bioavailability of the compound in cerebrospinal fluid (CSF) of a subject. 5. The pharmaceutical composition of claim 4, wherein the dodecyl-.beta.-D maltoside has a concentration in the range of about 0.01% to 1.0%. 6. The pharmaceutical composition of claim 4, in a format selected from the group consisting of a drop, a spray, an aerosol and a sustained-release format. 7. The pharmaceutical composition of claim 4, further comprising a mucosal delivery-enhancing agent selected from the group consisting of citric acid, sodium citrate, propylene glycol, glycerin, ascorbic acid, sodium metabisulfite, ethylenediaminetetraacetic acid (EDTA) disodium, benzalkonium chloride, sodium hydroxide, and combinations thereof.